Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection (Q37101552)

18 August 2017

1 reference

title

Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection (English)

1 reference

18 August 2017

1 reference

2

Caroline M Perry

1 reference

18 August 2017

Vanessa R Anderson

1

1 reference

18 August 2017

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

68

1 reference

18 August 2017

4

1 reference

18 August 2017

535-565

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200868040-00011

18 August 2017

0 references

cites work

Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults

1 reference

12 December 2020

Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers

1 reference

12 December 2020

A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections

1 reference

12 December 2020

In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups

1 reference

12 December 2020

Moxifloxacin: a review of its use in the management of bacterial infections

1 reference

12 December 2020

Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.

1 reference

12 December 2020

Surveillance of resistance in bacteria causing community-acquired respiratory tract infections

1 reference

12 December 2020

Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients

1 reference

12 December 2020

In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas

1 reference

12 December 2020

In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils

1 reference

12 December 2020

Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections.

1 reference

12 December 2020

Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial

1 reference

12 December 2020

Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

1 reference

12 December 2020

Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project

1 reference

12 December 2020

Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.

1 reference

12 December 2020

Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease

1 reference

12 December 2020

Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation

1 reference

12 December 2020

Levofloxacin: a review of its use in the treatment of bacterial infections in the United States

1 reference

12 December 2020

Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults

1 reference

12 December 2020

Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation

1 reference

12 December 2020

Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens

1 reference

12 December 2020

In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone

1 reference

12 December 2020

In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe

1 reference

12 December 2020

Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoni

1 reference

12 December 2020

Clinical practice guideline: adult sinusitis.

1 reference

12 December 2020

Management of urinary tract infections: historical perspective and current strategies: Part 2--Modern management

1 reference

12 December 2020

In vitro antibacterial activity and pharmacodynamics of new quinolones

1 reference

12 December 2020

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

1 reference

12 December 2020

Amoxicillin/clavulanic acid 2000mg/125mg extended release (XR): a review of its use in the treatment of respiratory tract infections in adults

1 reference

12 December 2020

Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option

1 reference

12 December 2020

A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia

1 reference

12 December 2020

Current antibiotic therapy for isolated urinary tract infections in women

1 reference

12 December 2020

Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study

1 reference

12 December 2020

Update on treatment guidelines for acute bacterial sinusitis

1 reference

12 December 2020

Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials

1 reference

12 December 2020

Guide to selection of fluoroquinolones in patients with lower respiratory tract infections

1 reference

12 December 2020

Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas

1 reference

12 December 2020

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

12 December 2020

Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing

1 reference

12 December 2020

Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values

1 reference

12 December 2020

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

1 reference

12 December 2020

Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.

1 reference

12 December 2020

Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States

1 reference

12 December 2020

The diagnosis and management of sinusitis: a practice parameter update.

1 reference

12 December 2020

Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa

1 reference

12 December 2020

The Alexander Project: the benefits from a decade of surveillance

1 reference

12 December 2020

Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.

1 reference

12 December 2020

Levofloxacin: an updated review of its use in the treatment of bacterial infections

1 reference

12 December 2020

Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms

1 reference

12 December 2020

Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

1 reference

12 December 2020

New insights in the treatment by levofloxacin

1 reference

12 December 2020

Antimicrobial resistance among invasive isolates of Streptococcus pneumoniae collected across Canada.

1 reference

12 December 2020

Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

1 reference

12 December 2020

Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose

1 reference

12 December 2020

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

1 reference

12 December 2020

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract

1 reference

12 December 2020

Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae

1 reference

12 December 2020

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

1 reference

12 December 2020

Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study

1 reference

12 December 2020

In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae

1 reference

12 December 2020

The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae

1 reference

12 December 2020

In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas

1 reference

12 December 2020

Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.

1 reference

12 December 2020

Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States

1 reference

12 December 2020

Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae

1 reference

12 December 2020

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

1 reference

12 December 2020

Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.

1 reference

12 December 2020

Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.

1 reference

12 December 2020

Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections

1 reference

12 December 2020

Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin

1 reference

12 December 2020

Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).

1 reference

12 December 2020

Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers

1 reference

12 December 2020

Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).

1 reference

12 December 2020

Bactericidal activity of levofloxacin against Mycoplasma pneumoniae

1 reference

12 December 2020

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia

1 reference

12 December 2020

Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005).

1 reference

12 December 2020

A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis

1 reference

12 December 2020

A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis

1 reference

12 December 2020

A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.

1 reference

12 December 2020

In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae

1 reference

12 December 2020

Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).

1 reference

12 December 2020

Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects

1 reference

12 December 2020

Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

1 reference

12 December 2020

Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

1 reference

12 December 2020

Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.

1 reference

12 December 2020

Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study

1 reference

12 December 2020

Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY An

1 reference

12 December 2020

10.2165/00003495-200868040-00011

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18318569